TRT Eligibility Simulator

Testosterone replacement therapy eligibility pathway — labs, symptoms, and shared decision-making.

Current Stage

—

—

Biochemical status

—

Symptom burden

—

Diagnostic confirmation

—

Eligibility

—

Morning total testosterone300 ng/dL

Symptom count present2

Confirmed low testosterone

Active symptom marker

Pathway stage node

Eligible candidacy zone

Reversible cause flag

Scroll for details

Symptom Criteria for Hypogonadism

Placeholder: core symptoms guide initial suspicion of low testosterone.

Low libido: Key symptom (Placeholder short note)
Fatigue: Key symptom (Placeholder short note)
Mood change: Key symptom (Placeholder short note)
≥3 symptoms: Threshold (Placeholder short note)

Recognizing symptom patterns

Placeholder: clinicians review symptom checklist before ordering labs.

Placeholder: symptoms alone never confirm diagnosis without labs.

Two Confirmed Morning Low-Testosterone Readings

Placeholder: diagnosis requires two separate morning total testosterone draws.

AM only: Draw time (Placeholder short note)
<300 ng/dL: Cutoff (Placeholder short note)
2 required: Repeat draws (Placeholder short note)
Total T: Assay (Placeholder short note)

Why two readings matter

Placeholder: single low value can be transient or lab error.

Placeholder: confirmed low readings anchor the diagnosis.

Ruling Out Reversible Causes

Placeholder: exclude pituitary, thyroid, medication, and lifestyle factors.

Pituitary: Check (Placeholder short note)
Thyroid: Check (Placeholder short note)
Medications: Check (Placeholder short note)
Obesity/sleep: Check (Placeholder short note)

Secondary cause workup

Placeholder: labs and history screen for reversible contributors.

Placeholder: treating underlying cause may resolve low testosterone.

Shared Decision-Making on Risks

Placeholder: patient and clinician weigh benefits against known risks.

Cardiovascular: Risk (Placeholder short note)
Fertility: Risk (Placeholder short note)
Prostate: Risk (Placeholder short note)
Polycythemia: Risk (Placeholder short note)

Discussing tradeoffs

Placeholder: informed consent covers monitoring and side effects.

Placeholder: shared decisions respect patient goals and risk tolerance.

Candidacy Determination

Placeholder: final eligibility combines labs, symptoms, and consent.

Eligible: Outcome (Placeholder short note)
Not eligible: Outcome (Placeholder short note)
Further workup: Outcome (Placeholder short note)
3 months: Follow-up (Placeholder short note)

Final determination

Placeholder: eligibility recommendation issued after full review.

Placeholder: ongoing monitoring follows any therapy decision.